Reema Mody - Publications, H-index & Citations

Dosing Patterns of Tirzepatide (TZP) in Patients with Type 2 Diabetes (T2D) from a Commercially Insured US Population

IF5.7

2025-04-04

PREAI

Mody, Reema; Desai, Karishma; Teng, Chia-Chen; Reznor, Gally; Stockbower, Grace; Grabner, Michael; Benneyworth, Brian D.

Real-World Effectiveness among Patients with Type 2 Diabetes (T2D) Initiating Tirzepatide (TZP)

IF7.5

2024-06-14

PREAI

Mody, Reema; Desai, Karishma; Teng, Chia-Chen; Reznor, Gally; Stockbower, Grace; Grabner, Michael; Benneyworth, Brian D.

Predicting Cardiovascular Risk in Participants Treated With Tirzepatide in the SURPASS 1-5 Trials

IF7.5

2024-06-14

PREAI

Mody, Reema; Desai, Karishma; Teng, Chia-Chen; Reznor, Gally; Stockbower, Grace; Grabner, Michael; Benneyworth, Brian D.

CIRCULATION

IF38.6

2023-11-07

PREAI

Wiese, Russell J.; Wang, Hui; Mody, Reema; Benneyworth, Brian D.

Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States 替吉帕肽与semaglutide 1.0 mg在美国2型糖尿病治疗中的长期成本效益分析

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison

IF5.7

2023-02-20

PREAI

Valentine, William J.; Hoog, Meredith; Mody, Reema; Belger, Mark; Pollock, Richard

Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States

IF5.7

2022-06-13

OAAI

Vadher, Karan; Patel, Hiren; Mody, Reema; Levine, Joshua A.; Hoog, Meredith; Cheng, Alice Y. Y.; Pantalone, Kevin M.; Sapin, Helene

Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice

IF3.6

2022-06-01

OAAI

Hoog, Meredith; Smith, Joseph L.; Yu, Maria; Peleshok, Jennifer; Mody, Reema; Grabner, Michael

The Health Care Resource Utilization and Costs Among Patients With Type 2 Diabetes and Either Cardiovascular Disease or Cardiovascular Risk Factors An Analysis of a US Health Insurance Database 2型糖尿病和心血管疾病或心血管危险因素患者的医疗资源利用和成本美国健康保险数据库的分析

IF3.6

2022-04-01

OAAI

Mody, Reema; Manjelievskaia, Janna; Marchlewicz, Elizabeth H.; Malik, Raleigh E.; Zimmerman, Nicole M.; Irwin, Debra E.; Yu, Maria

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND

IF3.6

2021-11-01

OAAI

Meyers, Juliana; Hoog, Meredith; Mody, Reema; Yu, Maria; Davis, Keith

CARDIOVASCULAR DIABETOLOGY

IF10.6

2021-09-25

OAAI

Konig, Manige; Riddle, Matthew C.; Colhoun, Helen M.; Branch, Kelley R.; Atisso, Charles M.; Lakshmanan, Mark C.; Mody, Reema; Raha, Sohini; Gerstein, Hertzel C.

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11

Greater Adherence and Persistence with Dulaglutide Compared with Semaglutide at 6-and 12-Months Follow-up in US Real-World Data

IF5.7

2021-06-29

OAAI

Bonora, Enzo; Frias, Juan P.; Tinahones, Francisco J.; Van, Joanna; Malik, Raleigh E.; Yu, Zhuoxin; Mody, Reema; Bethel, Angelyn; Kwan, Anita Y. M.; Cox, David A.

Impact of Early Initiation of Dulaglutide on MC in Patients with Type 2 Diabetes

IF7.5

2021-06-01

PREAI

Mody, Reema; Manjelievskaia, Janna; Yu, Maria; Marchlewicz, Elizabeth H.; Malik, Raleigh; Zimmerman, Nicole; Irwin, Debra E.

Are We There Yet? Increasing Use of Cardioprotective Antihyperglycemic Agents in Patients with T2D and CVD or CV Risk in the U.S

IF7.5

2021-06-01

PREAI

Hoog, Meredith; Smith, Joseph L.; Yu, Maria; Peleshok, Jennifer; Mody, Reema; Grabner, Michael

Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE study

IF7.5

2021-06-01

PREAI

Mody, Reema; Meyers, Juliana; Yu, Maria; Levine, Joshua A.; Davis, Keith

Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results

IF5.7

2020-12-13

OAAI

Boye, Kristina; Ross, Melissa; Mody, Reema; Konig, Manige; Gelhorn, Heather

Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatideBCise: 6-month follow-up fromUS real-worlddata

IF3.6

2020-11-01

OAAI

Mody, Reema; Yu, Maria; Grabner, Michael; Boye, Kristina; Teng, Chia-Chen; Kwan, Anita Y. M.

The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes

IF5.7

2020-10-11

OAAI

Mody, Reema; Yu, Maria; Nepal, Bal; Konig, Manige; Grabner, Michael

Dulaglutide Shows Sustained A1C Reduction: Two-Year US Real-World Study

IF3.6

2020-09-01

OAAI

Boye, Kristina S.; Mody, Reema; Lage, Maureen J.; Malik, Raleigh E.

Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND

IF7.5

2020-06-01

PREAI

Mody, Reema; Yu, Maria; Grabner, Michael; Boye, Kristina; Teng, Chia-Chen; Kwan, Anita